Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy.

ABSTRACT: New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize effor

SUBMITTER: Resa-Infante P 

PROVIDER: S-EPMC12327374 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature